Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant ; volume:36 ; number:6 ; day:20 ; month:4 ; year:2022 ; pages:649-658 ; date:6.2022
CNS drugs ; 36, Heft 6 (20.4.2022), 649-658, 6.2022
- Creator
-
Floden, Lysbeth
Hudgens, Stacie
Jamieson, Carol
Popova, Vanina
Drevets, Wayne C.
Cooper, Kimberly
Singh, Jaskaran
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-022-00916-2
- URN
-
urn:nbn:de:101:1-2022080221412670217478
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Floden, Lysbeth
- Hudgens, Stacie
- Jamieson, Carol
- Popova, Vanina
- Drevets, Wayne C.
- Cooper, Kimberly
- Singh, Jaskaran
- SpringerLink (Online service)
Other Objects (12)
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Personalized use of ketamine and esketamine for treatment-resistant depression
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Gender differences in obstructive sleep apnea with comorbid treatment-resistant depression
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Personalized use of ketamine and esketamine for treatment-resistant depression
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Gender differences in obstructive sleep apnea with comorbid treatment-resistant depression
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Personalized use of ketamine and esketamine for treatment-resistant depression
Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders : a case report
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Gender differences in obstructive sleep apnea with comorbid treatment-resistant depression
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials